Why the study?
Does alternate day statin and fibrate therapy improve postprandial dyslipidemia in patients with type 2 diabetes mellitus?
Does alternate day statin and fibrate therapy improve postprandial dyslipidemia in patients with type 2 diabetes mellitus?
Alternate day dosing of statins and fibrates may offer a logistically simpler yet effective approach to managing postprandial dyslipidemia in patients with type 2 diabetes.
May support simpler alternate-day regimens in T2DM; leaves open confirmation in randomized trials.
Postprandial lipemia represent an important risk factor for lifetime development of cardiovascular disease in patients with type 2 diabetes mellitus. Daily administration alone or combined statin and fibrate therapy has been shown to be an effective therapeutic approach but brings about serious logistics problem in our local setting. To address this concern, we report this observation where alternate day statin and fibrate treatment given alone or in combination in type 2 diabetes mellitus and similar effectiveness in lowering postprandial dyslipidemia has been obtained.
No takes yet. Share an insight, caveat, or question.
Mangelen et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: